Bridging Technology and Personalized Care in Psoriasis Management
The TELEPROM Psoriasis study highlights how telepharmacy and patient-reported outcomes improve the quality of life for patients with moderate-to-severe psoriasis.
Read MoreJan 29, 2025
The TELEPROM Psoriasis study highlights how telepharmacy and patient-reported outcomes improve the quality of life for patients with moderate-to-severe psoriasis.
Read MoreJan 28, 2025
GLI thresholds reduce COPD overdiagnosis in older smokers vs. GOLD, aligning severity with clinical signs and reducing unnecessary treatments.
Read MoreJan 22, 2025
Loneliness appears to be a more important risk factor for symptom exacerbations and acute health service use among adults with COPD than asthma.
Read MoreJan 22, 2025
Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.
Read MoreJan 22, 2025
Liso-cel shows durable efficacy in R/R CLL/SLL, with extended OS of 43.2 months, high uMRD rates, and consistent safety after nearly two years of follow-up.
Read MoreJan 22, 2025
Researchers at SABCS 2024 identified disparities and advised that male patients should be educated to recognize and seek care for early signs of breast cancer.
Read MoreJan 16, 2025
Combining manual therapy with exercise enhances pain relief and disability outcomes for low back pain.
Read MoreJan 16, 2025
The CLL 12 study found ibrutinib improved global health/physical function without overall survival benefits in early-stage, asymptomatic CLL.
Read MoreJan 16, 2025
On Tuesday, January 21, 2025, Joel Gelfand, MD, will join a panel of speakers to discuss the changing landscape of psoriasis and psoriatic arthritis.
Read MoreJan 16, 2025
Is there a session you’d like to see Physician’s Weekly cover at Maui Derm?
Read MoreJan 16, 2025
On Tuesday January 21, 2025 Julie Harper, MD, will lead a discussion on clinical updates for WINLEVI (clascoterone) Cream 1%.
Read MoreJan 13, 2025
Luis Sumoza, MD, discusses the BRUIN CLL-321 study presented during the ASH Annual Meeting, highlighting the importance of this research and how it will impact patient care.
Read MoreJan 13, 2025
The reasons why preeclampsia and other hypertensive disorders impact up to 8% of pregnancies are not fully understood, prompting calls for further research.
Read MoreJan 13, 2025
Routine screening for patient-reported outcomes may improve access to supportive care services among long-term metastatic breast cancer survivors.
Read MoreJan 8, 2025
This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.
Read MoreJan 8, 2025
A review of treatments for TP53m MCL found high response rates with targeted and CAR-T therapies but highlighted poor survival, urging innovative strategies.
Read MoreJan 8, 2025
First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.
Read MoreJan 8, 2025
A recent cohort study assessed the accuracy of the GOLD exacerbation history categories in estimating moderate and severe ECOPD and all-cause mortality in patients with COPD.
Read MoreJan 8, 2025
An online mindfulness-based stress reduction program reduced the symptomatic burden for patients with breast cancer, according to research from SABCS.
Read MoreJan 3, 2025
Elevations in biomarkers such as uterine artery pulsatility index and placental growth factor throughout pregnancy indicate preeclampsia risk.
Read More